Efficacy and safety of desloratadine/pseudoephedrine tablet, 2.5/120 mg two times a day, versus individual components in the treatment of patients with seasonal allergic rhinitis

Allergy and Asthma Proceedings

Volumn 26, Issue 5, 2005, Pages 391-396

  Chervinsky, Paul ^a   Nayak, Anjuli ^b   Rooklin, Anthony ^c   Danzig, Melvyn ^d  

^a Northeast Medical Research Associates   (United States)

^b UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^c Asthma and Allergy Research Associates   (United States)

^d MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DECONGESTIVE AGENT; DESLORATADINE; DRUG DERIVATIVE; EPHEDRINE; HISTAMINE H1 RECEPTOR ANTAGONIST; LORATADINE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG ADMINISTRATION; DRUG COMBINATION; FEMALE; HAY FEVER; HUMAN; MALE; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; TABLET; TREATMENT OUTCOME; UNITED STATES;

ADULT; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; EPHEDRINE; FEMALE; HISTAMINE H1 ANTAGONISTS, NON-SEDATING; HUMANS; LORATADINE; MALE; NASAL DECONGESTANTS; RHINITIS, ALLERGIC, SEASONAL; TABLETS; TREATMENT OUTCOME; UNITED STATES;

EID: 27644493653     PISSN: 10885412     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Bousquet J, Vignola AM, Campbell AM, and Michel FB. Pathophysiology of allergic rhinitis. Int Arch Allergy Immunol 110:207-218, 1996.
2. Howarth PH. The cellular basis for allergic rhinitis. Allergy 50:6-10, 1995.
3. Howarth PH, Wilson S, Lau L, and Rajakulasingam K. The nasal mast cell and rhinitis. Clin Exp Allergy 21(suppl 2):3-8, 1991.
4. Geha RS, and Meltzer EO. Desloratadine: A new, nonsedating, oral antihistamine. J Allergy Clin Immunol 107:751-762, 2001.
5. Norman P, Dihlmann A, and Rabasseda X. Desloratadine: A preclinical and clinical overview. Drugs Today 37:215-227, 2001.
6. Anthes J, Gilchrest H, Richard C, et al. Biochemical characterization of desloratadine, a potent antagonist of the human histamine H(1) receptor. Eur J Pharmacol 449:229-237, 2002.
7. Bachert C. Decongestant efficacy of desloratadine in patients with seasonal allergic rhinitis. Allergy 56(suppl 65):14-20, 2001.
8. Bachert C, Virchow JC, and Plenker A. Desloratadine in the treatment of seasonal allergic rhinitis: Results of a large observational study. Clin Drug Invest 22(suppl 2):43-52, 2002.
9. Baena-Cagnani CE. Desloratadine activity in concurrent seasonal allergic rhinitis and asthma. Allergy 56(suppl 65):21-27, 2001.
10. Kreutner W, Hey JA, Anthes J, et al. Preclinical pharmacology of desloratadine, a selective and nonsedating histamine H1 receptor antagonist, 1st communication: Receptor selectivity, antihistaminic activity, and antiallergenic effects. Arzneimittelforschung 50:345-352, 2000.
11. 1 receptor antagonist, 2nd communication: Lack of central nervous system and cardiovascular effects. Arzneimittelforschung 50:441-448. 2000.
12. Kanfer I, Dowse R, and Vuma V. Pharmacokinetics of oral decongestants. Pharmacotherapy 13:116S-128S, 1993.
13. Schoenwetter WF. Allergic rhinitis: Epidemiology and natural history. Allergy Asthma Proc 21:1-6, 2000.
14. Spector S. Overview of comorbid associations of allergic rhinitis. J Allergy Clin Immunol 99:S773-S780, 1997.
15. Horak F, Stubner P, Zieglmayer R, et al. Controlled comparison of the efficacy and safety of cetirizine 10 mg o.d. and fexofenadine 120 mg o.d. in reducing symptoms of seasonal allergic rhinitis. Int Arch Allergy Immunol 125:73-79, 2001.
16. Nayak A, Salmun LM, and Lorber RR. Desloratadine relieves nasal congestion in patients with seasonal allergic rhinitis. Allergy 55(suppl 63):193-194, 2000.
17. Berger WE, Schenkel EJ, and Mansfield LE. Safety and efficacy of desloratadine 5 mg in asthma patients with seasonal allergic rhinitis and nasal congestion. Ann Allergy Asthma Immunol 89:485-491, 2002.
18. Bronsky E, Boggs P, Findlay S, et al. Comparative efficacy and safety of a once-daily loratadine-pseudoephedrine combination versus its components alone and placebo in the management of seasonal allergic rhinitis. J Allergy Clin Immunol 96:139-147, 1995.
19. Corren J, Harris AG, Aaronson D, et al. Efficacy and safety of loratadine plus pseudoephedrine in patients with seasonal allergic rhinitis and mild asthma. J Allergy Clin Immunol 100:781-788. 1997; Erratum, J Allergy Clin Immunol 101:792, 1998.
20. Roman IJ, and Danzig M. Loratadine: A review of recent findings in pharmacology, pharmacokinetics, efficacy, and safety, with a look at its use in combination with pseudoephedrine. Clin Rev Allergy 11:89-110, 1993.
21. Sussman GL, Mason J, Compton D, et al. The efficacy and safety of fexofenadine HCl and pseudoephedrine, alone and in combination, in seasonal allergic rhinitis. J Allergy Clin Immunol 104:100-106, 1999.
22. Bertrand B, Jamart J, Marchal JL, and Arendt C. Cetirizine and pseudoephedrine retard alone and in combination in the treatment of perennial allergic rhinitis: A double-blind multicentre study. Rhinology 34:91-96, 1996.
23. American Academy of Allergy Asthma and Immunology (AAAAI). Conditions that may have an allergic component. In The Allergy Report, Vol. III. Milwaukee, WI: AAAAI, 1-7, 2000.